NAMS

Conviction 25HealthcareScan · Thu, Jun 25, 2026

NAMS$31.73-2.76%

ResistanceSupportVol 14Insider sell

Vol MA14 1.13M

Mar 26Apr 14May 1May 19Jun 8Jun 25

NewAmsterdam Pharma Co N.V.PHARMACEUTICAL PREPARATIONSwww.newamsterdampharma.com ↗

Price31.73

Change-2.76%

Gap+1.92%

Rel volume0.89×

Avg volume1.31M

Avg $ vol41.24M

SMA 2031.38

SMA 5032.68

SMA 20033.40

Price vs 50-2.89%

Price vs 200-5.00%

MA stackbearish

50/200 crossdeath · 7d

Supertrenddown · 35.38

RSI (14)49

MACD hist0.19

MACD crossbull · 1d

Stoch %K / %D63 / 66

ADX (14)16

+DI / −DI23 / 19

RSI divergence—

MACD divergence—

ATR %+5.36%

ADR %5.26%

52w high41.45

52w low18.11

From 52w high-23.45%

Above 52w low+75.21%

New 52w highNo

SqueezeOff

Bollinger width17.95%

%B0.56

Donchian pos34.51%

Donchian high36.73

Donchian low29.10

AVWAP (52w high)33.75

vs AVWAP high-6.00%

AVWAP (52w low)31.81

vs AVWAP low-0.24%

OBV trendDown

Chaikin MF (20)-0.15

Today vs 20d0.89×

Avg vol (14d)1.13M

Avg vol (20d)1.31M

Avg $ vol (20d)41.24M

Market cap3.71B

RS 3m (vs SPY)-3.71%

RS 6m (vs SPY)-14.80%

RS line new highNo

Trend template4/8

Technical rank28.5

1 week+5.24%

1 month-12.13%

3 months+2.32%

6 months-13.04%

1 year+72.45%

YTD-9.86%

P/E-18.20

P/B5.58

P/S164.84

P/FCF-25.06

EPS-1.72

Div yield—

ROE-30.64%

ROA-27.82%

Debt/Eq—

Current9.76

EV/EBITDA-14.42

Gross margin—

Net margin-905.74%

Rev growth-50.61%

EPS growth15.64%

Price target47.86

Target upside50.84%

Analyst ratingBuy

Institutional106.23%

Ent. value3.25B

Revenue3.04M

Net income-48.44M

Gross profit—

Free cash flow-148.03M

IndustryPHARMACEUTICAL PREPARATIONS

ExchangeNasdaq

Shares out116.9M

Employees100

ListedWed, Nov 23, 2022

Free float62.23M

Float %53.2%

Short interest8.1M

Days to cover6.2d

Short volume58.4%

Squeeze score63 / 100

Next earningsWed, Aug 5, 2026 (41d)

EPS forecast−$0.48 · 4 est

Last EPS vs est−$0.40 vs −$0.46

Last surprise+13.0% beat

Setup gradeD

Conviction25 / 100

Pattern quality—

Tech rank28.5 / 100

Group rank50 / 100

Status laneNo active setup

Setup direction—

Pattern family

Resistance39.77

Support29.11

Days since event—

Candle confirm—

News sentiment—

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in NAMS

All disclosures →

No recent disclosed trades by Congress in NAMS. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in NAMS · 2 buys · 3 sells

Insider	Side	Shares	Value	Traded	Filed
Kooij Louise Frederika Chief Accounting Officer · Option (right to buy) · 2026-05-26	Exercise	5K	$0	2026-05-26	2026-05-27
Kooij Louise Frederika Chief Accounting Officer · Ordinary Shares · 2026-05-26	Exercise	5K	$55K	2026-05-26	2026-05-27
Kooij Louise Frederika Chief Accounting Officer · Ordinary Shares · 2026-05-26	Exercise	60K	$600K	2026-05-26	2026-05-27
Kooij Louise Frederika Chief Accounting Officer · Ordinary Shares · 2026-05-26	Sell	65K	$2.3M	2026-05-26	2026-05-27
Kooij Louise Frederika Chief Accounting Officer · Option (right to buy) · 2026-05-26	Exercise	60K	$0	2026-05-26	2026-05-27

SEC filings

EDGAR filings in NAMS · 2 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.

Start free — 7-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.